SciSparc Stock Surges 37% Following Strategic Pivot to Agentic AI and Cybersecurity

SciSparc Announces Strategic Pivot to Agentic AI

SciSparc announced a full strategic transformation into agentic artificial intelligence technologies on October 15, 2026, marking a significant departure from its pharmaceutical roots2

2

. The Tel Aviv-based company revealed plans to evaluate technologies, companies, and business opportunities across the agentic AI ecosystem, with declared focus on cybersecurity and financial applications1

1

2

2

. Agentic AI refers to autonomous systems capable of independently planning and executing tasks toward defined objectives, representing one of the market's most closely watched technology themes2

2

.

SciSparc Stock Surge Defies Market Headwinds

SPRC shares jumped 37% in pre-market trading, reaching as high as $5.04 from a prior close of $3.682

2

. During Thursday's session, the stock gained over 18%, closing at $4.2901

1

. Trading volume surged dramatically, with nearly 29.94 million shares changing hands—approximately 172 times the 100-day average volume of 174,561 shares1

1

. This rally occurred despite the NASDAQ falling 1.1% amid hotter-than-expected inflation data that pressured AI infrastructure and semiconductor stocks2

2

. With a market capitalization of just $2.29 million, SciSparc operates as a micro-cap stock, making it susceptible to sharp price swings and heightened volatility1

1

.

Building Blocks for AI Transformation

The strategic pivot did not emerge without precedent. SciSparc first signaled its ambitions in the agentic AI market through a July 27, 2026 decision to pursue AI-driven business opportunities1

1

2

2

. On August 26, 2026, the company established a scientific advisory board focused on AI and cybersecurity to support its expansion into these areas1

1

2

2

. However, the company cautioned that its evaluation efforts may not lead to transactions, commercial agreements, or revenue generation1

1

2

2

. No acquisitions, partnerships, or commercial agreements have been announced in connection with the strategy1

1

.

Pharmaceutical Business Remains Operational

SciSparc currently operates as a clinical-stage pharmaceutical developer through its majority-owned subsidiary NeuroThera Labs2

2

. The pharmaceutical business focuses on cannabinoid-based treatments, including THC and cannabidiol products1

1

. The company's SCI-110 program targets Tourette syndrome, Alzheimer's disease, and agitation, while SCI-210 addresses autism spectrum disorder and status epilepticus1

1

. Through NeuroThera, SciSparc also maintains a controlling stake in a business selling hemp seed oil-based products on Amazon's marketplace1

1

.

Market Impact and Investor Considerations

The pre-market surge was driven primarily by speculative momentum rather than institutional conviction, as no fresh analyst upgrades accompanied the announcement2

2

. The most recent analyst ratings on file remained a hold and a sell2

2

. The combination of a headline-grabbing strategic transformation into agentic AI and a small-float stock structure created conditions for an outsized move, even as the broader technology sector struggled under macroeconomic headwinds2

2

. Investors should watch for concrete announcements regarding partnerships, acquisitions, or commercial agreements that could validate the company's entry into the agentic AI ecosystem and cybersecurity markets. The company's ability to execute on this transformation while maintaining its existing pharmaceutical operations will determine whether this strategic pivot delivers long-term value beyond initial trading excitement.